Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

• Adult patient aged ≥ 18 years

• Written informed consent

• Histologically (squamous or non-squamous) or cytologically documented locallyadvanced NSCLC not eligible for surgical resection and/or definitive chemoradiation,or metastatic NSCLC

• No prior systemic treatment for locally advanced or metastatic NSCLC

• High tumor cell PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] based ondocumented status as determined by an approved test

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

• Measurable disease as determined by RECIST v1.1

Exclusion Criteria:

• Tumors harboring driver mutations/genetic aberrations for which targeted therapiesare approved as frontline treatment (e.g. EGFR mutation, ALK fusion oncogene, ROS1aberrations)

• Prior immune checkpoint inhibitor therapy

• Active brain metastases

• Participants with active and uncontrolled hepatitis B virus (HBV) or hepatitis Cvirus (HCV) infection

• Uncontrolled HIV infection. Participants with HIV who have controlled infection (undetectable viral load and CD4 count above 350 either spontaneously or on a stableantiviral regimen) are allowed to enroll

• Active, known or suspected autoimmune disease or immune deficiency

• History of hypersensitivity reactions to any ingredient of the investigationalmedicinal product (IMP) and other monoclonal antibody (mAbs) and/or their excipients

• History of interstitial lung disease, idiopathic pulmonary fibrosis, drug-inducedpneumonitis, idiopathic pneumonitis or active pneumonitis ≥ grade 2

• History of inflammatory bowel disease or colitis ≥ grade 2

• History of hemophagocytic lymphohistiocytosis.

• Systemic chronic steroid therapy (>10mg/d prednisone or equivalent)

• Active infection, including infection requiring systemic antibiotic therapy

• Pregnant or breast-feeding (lactating) women

• Participants with a history of allogeneic organ transplantation (e.g., stem cell orsolid organ transplant)

• Any medical condition that would in the investigator's judgement prevent theparticipant's participation in the clinical study